Plasmepsins I and II (PM I and II) are aspartic proteases involved in the initial steps of Plasmodium hemoglobin degradation. They are attractive targets for antimalarial drug development. The two enzymes are 73% identical, yet have different substrate and inhibitor specificities. The x-ray structures of proform and mature PM II have been determined, but models of PM I do not adequately explain the selectivity of the two proteases. To better understand the basis of these recognition differences, we have identified nine residues of PM II that are in proximity to the inhibitor pepstatin in the crystal structure and differ in PM I. We mutated these residues in PM II to the cognate amino acids of PM I. Kinetic parameters for substrate and inhibitors for the PM II-mutant were similar to those of PM II-wild type (WT). Cleavage specificity was assessed using hemoglobin or a random decamer peptide library as substrate. Again, PM II-mutant behaved like PM II-WT rather than PM I-WT. These results indicate that differences in plasmepsin specificity depend more on conformational differences from distant sites than on specific active site variation.
Malaria is a disease caused by parasites of the genus Plasmodium. The disease afflicts several hundred million and kills up to 3 million annually, mainly children (1) . At the intraerythrocytic stage, these parasites consume hemoglobin as a major nutrient source for parasite growth and maturation. Hemoglobin degradation is mediated by the action of several digestive enzymes in the acidic food vacuole. Plasmepsins are aspartic proteases found in the food vacuole that are essential for degradation of hemoglobin. There appear to be four plasmepsins involved in hemoglobin degradation in the food vacuole of Plasmodium falciparum (2) . PM I makes an initial cleavage at Phe-33-Leu-34 on the ␣-globin chain of hemoglobin (3) , presumably leading to the unraveling of the hemoglobin molecule such that further proteolysis by PM II, PM IV, histoaspartic protease (HAP), falcipains, and facilysin can rapidly proceed (2, 4 -8) . The small peptides formed from the action of these enzymes are converted to free amino acids by aminopeptidases and perhaps other enzymes (9, 10) .
The World Health Organization has recognized the plasmepsins as attractive targets for the design of novel chemotherapeutic compounds for the treatment of malaria (11) . The inhibition of their activities by peptidomimetic compounds specific for aspartic proteases results in death of the parasites (12) (13) (14) . The elucidation of structure-activity relationships for these enzymes will facilitate the development of potent, specific inhibitors. Structures of PM II in both proforms and mature forms are available (15, 16) . Unfortunately, the structure of PM I is still unknown, even though it is important in the first step of hemoglobin degradation. Active, recombinant PM I has been generated (13) , but its limited yield and solubility have prevented its crystallization.
Based on the structure of PM II co-crystallized with pepstatin, a specific peptide inhibitor of aspartic proteases (15) , amino acid residues in the active site of PM II in proximity to the pepstatin molecule were compared with the corresponding amino acids in PM I. Nine amino acids that differed between the two enzymes were chosen for site-directed mutagenesis. We hypothesized that putting these nine amino acid residues of PM I in the PM II scaffold structure would give rise to a specificity similar to that of PM I. We hoped that this approach would allow us to obtain a structure of the PM I active site on the soluble PM II structure core. Unexpectedly, our data show that engineering a PM II with the active site surface of PM I largely maintains the PM II substrate and inhibitor specificity.
EXPERIMENTAL PROCEDURES

Reagents-QuikChange
TM site-directed mutagenesis kit was obtained from Stratagene (La Jolla, CA). Pepstatin A was obtained from ICN (Costa Mesa, CA). P1 inhibitor was obtained from J. Erickson, NCI-Frederick, MD. SC-50083 inhibitor was obtained from Searle Pharmaceuticals, St. Louis, MO. All other reagents were from Sigma. Plasmepsin I pET3a plasmids were obtained from Dr. Richard P. Moon (Hoffmann-La Roche).
Mutation Constructs-Based on the structure of PM II co-crystallized with pepstatin, nine amino acid residues were chosen for mutation. Using the QuikChange TM site-directed mutagenesis kit following manufacturer's directions, mutations in the active site of the PM II gene were generated. Mutations were done in several steps using the different pairs of mutagenic primers encoding the amino acid residues in the active site of PM I to replace the amino acid residues in the active site of PM II.
The mutagenic primers encoded the target I14V and F16Y (5Ј-GAT-TTCCAAAATGTGATGTATTATGGTGATGCAGAAGTTGG-3Ј, 5Ј-CAT-CACCATAATACATCACATTTTGGAAATCTACTAATTCG-3Ј), T114A (5Ј-CCAGAGTATACGCTGGTTCGAATCCATTAGTATC-3Ј, 5Ј-GATTC-GAACCAGCGTATACTCTGGGCCAGTTTG-3Ј), A117L, S118G, and T119Q (5Ј-CCAAGGATACCATCAAACTGGCCCAGAGTATAAGTTGG-TTCGAATCC-3Ј, 5Ј-CGAACCAACTTATACTCTGGGCCAGTTTGATG-GTATCCTTGGTTTAGG-3Ј), A219S (5Ј-GTGGTACTAGTTCTATTACT-GTACCAACTGAC-3Ј, 5Ј-GGTACAGTAATAGAACTAGTACCACTATC- TAC-3Ј), L292V and F294L (5Ј-TTGGTACTGGCAGATCCACTCCTAT-GATATTAAGCATAC-3Ј, 5Ј-ATATCATAGGAGTGGATCTGCCAGTAC-CAACCTTTATTCTAG-3Ј). Plasmid DNA from mutants was sequenced to confirm that only the desired mutations were incorporated.
Expression and Purification of Recombinant Plasmepsins-The pET3a plasmids containing plasmepsin sequences were transformed into Escherichia coli BL21(DE3)pLysS. For PM II-WT and PM IImutant, transformants were grown at 37°C in LB broth containing 100 g/ml ampicillin and 170 g/ml chloramphenicol. At A 600 of 0.5, isopropyl-1-thio-␤-D-galactopyranoside was added to 0.5 mM, and culture was grown at 37°C for 5 h. For PM I-WT, transformants were cultured in super medium (25 g/liter bacto-tryptone; 15 g/liter bacto-yeast extract; 10 g/liter NaCl) containing 50 g/ml ampicillin and 35 g/ml of chloramphenicol. Upon reaching an A 600 of 0.8, they were induced for 2 h by addition of 0.5 mM isopropyl-1-thio-␤-D-galactopyranoside. After cells were harvested by centrifugation (5000 ϫ g, 15 min, 4°C) and lysed by sonication, protein expression was analyzed by using 12.5% SDS-PAGE.
For PM II-WT and II-mutant, the recombinant proplasmepsins were expressed as inclusion bodies, which were resuspended in 20 mM TrisHCl, pH 7.4, 150 mM NaCl, 5 mM dithiothreitol (buffer A) and sequentially washed with: 1) 1% CHAPS 1 in buffer A, twice; 2) 1 M NaCl in buffer A; 3) 1 M urea in buffer A, and 4) buffer A. The washed pellet was solubilized in 50 mM Tris buffer, pH 7.4, containing 6 M urea, 500 mM NaCl, 50 mM dithiothreitol, and 1 mM EDTA and then dialyzed in 50 mM Tris buffer, pH 7.4, containing 6 M urea, 50 mM dithiothreitol, and 1 mM EDTA (buffer B) overnight at 4°C. The dialysate was applied to a mono-Q-Sepharose column (Amersham Biosciences). The column was eluted with a linear NaCl gradient (0 -1 M in buffer B), and the fractions containing proplasmepsins, as analyzed by SDS-PAGE, were pooled and diluted with the same buffer to 1 mg/ml protein concentration. Refolding of proplasmepsins was initiated by stepwise dialysis for 4 h against five times the original volume of 20 mM Tris-HCl, pH 8.0, in Spectrapor dialysis tubing (MWCO 12-14 kDa) at 4°C. The dialysis buffer was changed four times. The dialysate was centrifuged to remove any precipitate and applied to a mono-Q-Sepharose column (8 ml) equilibrated in 20 mM Tris, pH 8.0, buffer at 4°C using an Amersham Biosciences FPLC. The column was eluted with a linear NaCl gradient (0 -1 M) in the same buffer. The fractions containing proplasmepsins were pooled and stored at 4°C.
For PM I-WT, the recombinant proplasmepsin (construct and basic procedure of Moon, Ref. 13) in inclusion bodies was resuspended in wash buffer (100 mM Tris-HCl, pH 8.0, 10% glycerol, 1 mM MgSO 4 , 150 mM NaCl, 0.1% Triton X-100, 5 mM EDTA containing protease inhibitor (⑀-aminocaproic acid) and benzonase (RNase and DNase)), and sequentially washed with: 1) 1% CHAPS in wash buffer, twice; 2) 0.5 M NaCl in wash buffer; 3) wash buffer; and 4) 2 M urea in wash buffer. The final washed pellet was solubilized in 50 ml of 8 M urea, 20 mM Tris-HCl, pH 8.0, and 1 mM EDTA containing protease inhibitors (⑀-aminocaproic acid and benzamidine-HCl). After centrifugation to remove the precipitate, the solution was dialyzed against 1 liter of Aq buffer (20 mM Tris-HCl, pH 8.0, 6 M urea, 1 mM EDTA) overnight at 4°C and then applied to a mono-Q-Sepharose column (8 ml). The column was eluted with a linear NaCl gradient (0 -1 M in Aq buffer), and the fractions containing PM I-WT, as analyzed by SDS-PAGE, were pooled and dialyzed against 1 liter of Aphos buffer (20 mM Tris-HCl, pH 8.0, 10% glycerol, 1 mM EDTA, and 6 M urea) overnight at 4°C. The dialysate was applied onto a 1-ml heparin-Sepharose column (Amersham Biosciences) and eluted with a linear NaCl gradient (0 -0.5 M) in Aphos buffer. Fractions containing PM I-WT were pooled, the protein concentration was determined, and the sample was diluted to 0.1 mg of protein/ml with Aphos buffer. Refolding of PM I-WT was done by stepwise dialysis. First, PM I-WT was dialyzed against 1 liter of refolding buffer 1 (25 mM glycylglycine, pH 9.5, 40 mM arginine, 0.5 M NaCl, 1 mM EDTA, 25% glycerol, 4 mM GSH and 0.4 mM GSSG) for 2 days at 10°C with two buffer changes. Second, the solution was dialyzed against 1 liter of refolding buffer 2 (20 mM glycylglycine, pH 9.0, 25% glycerol, 0.15 M NaCl, 1 mM EDTA, 0.01% Triton X-100, 50 mM (NH 4 ) 2 SO 4 ) for 2 days at 10°C with two buffer changes. Protein was concentrated to 4 ml and dialyzed overnight at 4°C against 500 ml of buffer containing 20 mM glycylglycine, pH 9.0, 5% glycerol, 1 mM EDTA, and 0.15 M NaCl. PM I-WT was concentrated and kept at 4°C for further characterization.
Activation of Proplasmepsins-Prior to assay, the mature forms of plasmepsins were generated by adding one-tenth volume of 1 M sodium acetate, pH 5.0, for 24 h at room temperature. Autocatalytic processing of each zymogen (43 kDa) to mature form (37 kDa) was monitored by SDS-PAGE.
Determination of Plasmepsin Activity-The fluorogenic substrate used for the assay based on the sequence surrounding the Hb ␣ Phe33-Leu34 initial cleavage site (3) was DABCYL-GABA-Glu-Arg-Met-PheLeu-Ser-Phe-Pro-GABA-EDANS. This peptide sequence is flanked by a fluorophore group, EDANS, and a quenching group, DABCYL (17) . Fluorescence is quenched in the intact peptide, and quenching is relieved when the peptide is cleaved by enzyme.
The assay was performed in quartz cuvettes with a PerkinElmer Life Sciences LS50B fluorometer at an excitation wavelength of 336 nm, slit width of 5 nm, and emission wavelength of 490 nm, slit width of 10 nm at 37°C with samples containing fluorogenic substrate, 100 mM sodium acetate, pH 5.0, 10% glycerol, and 0.01% Tween 20. K m and V max values were determined by measurement of initial velocities in duplicate or triplicate with at least six fluorogenic substrate concentrations. The k cat value was calculated from the following equation.
For K i determinations, inhibitors were equilibrated with enzyme at room temperature for 5 min followed by the addition of fluorogenic substrate stock. The change of fluorescence intensity was measured as a function of time. Assays were performed in duplicate or triplicate at five to six inhibitor concentrations for each K i determination. Data were fitted by nonlinear regression analysis to the equation derived by Williams and Morrison (18). 
3)
The precise concentration of each PM II and I preparation was determined by active site titration with pepstatin as described previously (19, 20) .
Hemoglobin Degradation-Human hemoglobin A (150 g) was incubated with PM I-WT, II-WT, and II-mutant in 500 l of 100 mM sodium acetate, pH 5.0, 10% glycerol, and 0.01% Tween 20 at 37°C for various   FIG. 3 . Analysis of random 10-mer peptide cleavage by plasmepsins. A random peptide substrate was digested by PM I-WT, II-WT, and II-mutant at pH 5.0, 37°C for 1 h. Cleavage preferences were analyzed by N-terminal amino acid sequencing. Data are normalized so that a value of 1 corresponds to the average quantity per amino acid in a given sequencing cycle. Because of interfering background peaks, glycine, threonine, and arginine could not be reliably quantitated and therefore were omitted.
TABLE I
Kinetic parameters of plasmepsins using a fluorogenic substrate DABCYL-GABA-Glu-Arg-Met-Phe*Leu-Ser-Phe-Pro-GABA-EDANS (17) . Initial rates were measured at 37°C using 1-5 nM enzyme. times. The reaction was stopped by adding 100 l of glacial acetic acid. The digest was subjected to reverse phase-HPLC using a RP-18 spheri-5 column, 1 mm ϫ 25 cm (Applied Biosystems) in mobile phase containing 0.1% trifluoroacetic acid with an accelerating (nonlinear) gradient of 18 -60% acetonitrile at 80 l/min over 60 min and with detection at 214 nm.
Random Peptide Substrate and N-terminal Amino Acid
Sequencing-A random peptide, acetyl-Xaa 10 -Lys(biotin) was synthesized, where X ϭ all 20 amino acids except cysteine. 20 M of random peptide substrate was incubated with PM I-WT, II-WT, and II-mutant in 100 mM sodium acetate, pH 5.0, 10% glycerol, and 0.01% Tween 20 at 37°C for various times and heated to 100°C for 5 min. The digest was sent for N-terminal amino acid sequencing. Amino acid preference in a given cycle was calculated by normalizing the amount of a particular residue to the average amount per amino acid residue in that cycle. Thus, a residue with an average quantity for that cycle has a value of 1. The data were corrected for bias present in the random peptide library by dividing each value by the relative amount of that particular amino acid in the starting mixture.
RESULTS
PM I and II are homologous, hemoglobin-degrading aspartic proteases. The mature enzyme sequences are 73% identical (85% homologous). Despite this, the two hydrolases display quite different substrate and inhibitor specificities. To better understand the basis for this difference, we examined the crystal structure of PM II bound to the inhibitor, pepstatin, and identified residues in the active site that are in contact with inhibitor. Nine such amino acids differ between PM I and PM II (Fig. 1) . We changed all nine amino acids in the recombinant PM II background to the cognate residues found in PM I. We compared enzyme properties of the mutant PM II to those of wild-type PM I and II. Heterologous expression of recombinant PM I-WT, PM II-WT, and PM II-mutant yielded products of 43 kDa as determined by SDS-PAGE. Activation of these proplasmepsins by lowering the pH to 5 produced the 37-kDa mature forms (Fig. 2) . Table I shows the kinetic parameters of PM I-WT, PM II-WT, and PM II-mutant. Using a fluorogenic peptide based on the initial hemoglobin cleavage site, the k cat , K m , and k cat /K m values were comparable for PM II-WT and PM II-mutant. In contrast, these values differed for PM I-WT; most dramatically, the PM I-WT specificity constant (k cat /K m ) was about 10-fold lower than those of the PM II enzymes. Table II shows an assessment of the ability of two different compounds to inhibit the plasmepsins. Similar K i values were measured for PM II-WT and PM II-mutant with the tight binding inhibitor, pepstatin. PM I-WT had a K i value an order of magnitude higher. Another inhibitor with differential ability to inhibit PM I and II was studied; because of limited compound availability, inhibition over a range of inhibitor concentration was measured at fixed substrate concentration to yield IC 50 values. The IC 50 of SC50083 for PM I-WT is 30-fold lower than that of PM II-WT. The IC 50 of PM II-mutant is similar to that of PM II-WT.
We analyzed the ability of the three enzymes to cleave a random decamer peptide library. N-terminal amino acid sequencing was performed after a 1-h incubation to determine the amino acid preference on the PЈ side of the substrate (Fig.  3) . Use of a similar dodecamer in other systems has been reported (21) . The most dramatic preferences are seen at the P1Ј position, where PM II-WT and PM II-mutant both prefer leucine about 4-fold more than the average amino acid and methionine about 2-fold. PM I-WT has a similar specificity, with a slightly diminished preference for these two residues and an increased preference for serine at P1Ј. At P2Ј, serine was preferred by each enzyme. At P3Ј-P5Ј (not shown, variance Ͻ2-fold), amino acid preferences are on a much smaller scale and are comparable among the three plasmepsins (data not shown). Similar results were obtained from 4-h and overnight incubations of the random peptide substrate with each plasmepsin (data not shown).
To extend the results beyond use of peptides and peptide-like compounds, the natural substrate hemoglobin was incubated with each of the three enzymes. Fig. 4 shows the C18-reverse phase HPLC elution profile of peptide products. For a 4-h incubation, the PM II-mutant profile is similar to PM II-WT profile, but the PM I-WT profile is different. For overnight incubation, there are five major peaks of peptide products that differ between wild-type PM I and II. The PM II-mutant profile shares the PM II-WT profile at four of these sites. DISCUSSION PM I and II are highly homologous enzymes but have different affinities for substrates and inhibitors. We have mutated the PM II active site so that its surface mimics that of PM I. Surprisingly, the enzyme specificity is essentially unchanged from the parent enzyme. Based on the PM II crystal structure, Silva et al. (15) suggested three amino acids that vary between PM I and II that might be important in selectivity: Thr-114, Leu-292, Phe-294. Our PM II-mutant includes these three changes, yet specificity was not altered. In some aspartic proteases, the polyproline loop can have interactions with substrate. This loop is divergent between the two plasmepsins. However, a swap of PM I and II loops has been carried out without effect on specificity (17) . Consistent with this, the loop does not appear to contact pepstatin in the crystal structure of PM II (15) . Although the high similarity of the two enzymes suggests the same overall folding topology, our findings indicated that there must be sufficient structural differences other than active site residues that influence selectivity of the plasmepsins.
The proform and mature form of PM II may be regarded as two proteins with the same active site residues but different activity. Khan et al. (22) have shown that this activity disparity is a result of alteration in active site conformation and not of active site blockage. Upon enzyme activation, the conformational change leads to the formation of a functional PM II active site (22) . For the case of PM I and PM II, it is possible that amino acid residues further away from the active site might cause some differences in their active site conformation and hence the differences in enzyme activity. The implication of our results is that differences in amino acid residues distant from the active site may play a significant role in determining spec- 15 h (B) . The digest was fractionated by HPLC using an RP-18 column with an acetonitrile gradient. * denotes peak that varies significantly between profiles at 15 h. ificity differences between two similar enzymes.
Interestingly, the most dramatic range of PM II amino acid preference in the random peptide analysis was seen at the P1Ј position. This position has not been extensively evaluated in other assays where the P1Ј residue was fixed as a chromogenic reporter. As would be expected from previous analysis of globin cleavage sites (6), PM II strongly preferred hydrophobic amino acids at the P1Ј site. Proline was also accepted at this position, as is the case for the human immunodeficiency virus protease (23) . The P1Ј preference for leucine over the least favored amino acids was Ͼ50-fold. In contrast, at each of the other positions (P2Ј-P5Ј), all amino acids were tolerated within a 7-fold range.
This work gives us insight into the importance of the overall fold of a protein molecule on substrate specificity. Even in quite similar proteins, the geometry of the active site, not just the surface side chains, can be different enough to affect specificity. We have much to learn about the PM I active site that can not be gleaned from homology modeling.
